The Drug is Only Half the Breakthrough [STAT Summit 2026 Review #21]

Report 21. The Drug is Only Half the Breakthrough

Part I. English Version

1. Event / Date & Time

Event: The Drug is Only Half the Breakthrough | Sponsored by DaVita

Conference: STAT Summit 2026

Date & Time: October 15, 2026 | 9:55 AM EDT

2. Participants

Speakers

- Misha Palecek — Chief Transformation Officer, DaVita

Moderator

- Zachary Tracer — Senior Editor, Business and Policy, STAT

3. Summary

Renal Therapeutic Advances: SGLT2 inhibitors and GLP-1 therapies were described as improving outcomes for people with chronic kidney disease.

Care Delivery Innovation: DaVita argued that integrated care, coordinated data and patient engagement are necessary for drug benefits to reach patients.

Value-Based Models: Collaboration with payers, AI-enabled care management and payment reform were presented as components of scalable kidney-care transformation.

4. Main Discussion

New Medicines for Chronic Kidney Disease

Palecek said SGLT2 inhibitors can slow kidney-disease progression by approximately 30–40%. He also cited DaVita’s figures indicating that GLP-1 use among dialysis-starting patients was associated with 9% fewer hospitalizations over six months and a 17% mortality improvement. These were company-presented estimates, not independently evaluated trial findings in the session.

Palecek placed the recent availability of SGLT2 and GLP-1 medicines against a history of limited options for people with chronic kidney disease. He cited a 30–40% slower progression of kidney disease with SGLT2 treatment and company-presented observations of reduced hospitalizations and improved mortality among certain patients on GLP-1 therapy who began dialysis. The distinction between these figures and independently reviewed clinical evidence is important because the session did not present full study designs, confidence intervals or patient-selection criteria. His main point was nevertheless clear: medicines can meaningfully change care trajectories, but their benefits depend on patients receiving appropriate prescriptions, understanding their conditions and remaining engaged over time.

Palecek’s account made a distinction between evidence that a drug works and the ability of a delivery system to translate that evidence into population-level benefit. He cited SGLT2 inhibitors as slowing kidney-disease progression by roughly 30–40%, and described benefits observed among chronic kidney disease patients using GLP-1 therapies, including changes in hospitalization and mortality after dialysis initiation. Those figures were presented by the speaker and should not be read as the results of an independently reviewed comparison in this report. The practical challenge is identifying patients early, prescribing appropriate therapies and supporting their continued use when renal, metabolic and cardiovascular conditions frequently coexist.

Integrated Kidney Care for Multiple Conditions

DaVita’s integrated kidney care model was described as serving approximately 80,000 people and managing kidney, cardiovascular and metabolic conditions together. Palecek argued that medicines alone are insufficient without support for prescriptions, lifestyle change, prevention and coordination across providers.

The adoption gap was one of the most concrete operational problems discussed. Palecek estimated that 85–90% of certain patients with late-stage chronic kidney disease should be receiving a relevant medicine, whereas only about 30–35% of the patients seen when entering DaVita’s care were already taking it. He also said that roughly 60% of people in the United States who begin dialysis had not realized their kidney function was deteriorating. These estimates were provided orally and should not be treated as standardized national prevalence measurements. They illustrated missed opportunities for timely diagnosis, identification of eligible patients, communication between specialists and primary-care clinicians, and follow-up before a person reaches dialysis.

DaVita’s integrated kidney care model was described as a response to this coordination problem. Palecek said the program supports about 80,000 patients and seeks to manage needs that extend beyond dialysis itself. Clinical outreach, medication coordination, chronic-disease monitoring and help navigating services were discussed as aspects of a wider care relationship. He also described arrangements with Medicare Advantage plans in which attributed patients become the responsibility of an integrated care team. This arrangement shifts attention from isolated treatment encounters to proactive management of people who are at risk of worsening disease. Its value nevertheless depends on execution, coverage design and the quality of measurements used to evaluate outcomes.

Data, AI and Payment Alignment

Palecek outlined care coordination built on payer and provider data, algorithms that recommend next actions, and support between clinical visits. He emphasized aligning payment incentives and identified CMS Innovation Center kidney-care initiatives as an important policy context. The approach seeks to identify undiagnosed patients and improve medication use and follow-up.

DaVita’s integrated approach was described as looking beyond the hours a person spends in a dialysis center. Care teams monitor concurrent metabolic and cardiovascular conditions and help coordinate care across specialists, payers and everyday life. Dialysis itself can occupy about 12 hours per week in a clinic, a commitment that illustrates the personal and economic consequences of late-stage disease. Palecek discussed identifying practical actions from longitudinal clinical and claims data, such as whether a person may need a follow-up appointment or an evidence-based medicine. The envisioned digital tools support care teams rather than substituting for nephrologists’ decisions. Implementation also depends on whether the service model can be reimbursed sustainably.

Data tools and AI were discussed as supporting services, not substitutes for nephrologists or relationships with patients. A large program must determine which individuals most urgently need outreach, which missed appointments or medication gaps require follow-up and when a specialist should intervene. Palecek linked digital innovation to workforce efficiency and better continuity, but the session did not establish that a particular algorithm independently causes better survival. The more defensible lesson is organizational: therapeutic innovation and service innovation are interdependent. Health systems need mechanisms for identifying eligible patients, adapting care to multiple conditions and feeding observed outcomes back into program design.

The underuse of established medicines was a particularly striking implementation gap. Palecek said that, for patients with late-stage chronic kidney disease, nephrologists might regard ACE inhibitors or angiotensin receptor blockers as appropriate for roughly 85–90% of patients, yet DaVita observed use in only about 30–35% of patients when care began. He presented this contrast as an example of the value of early identification and protocol-guided follow-up rather than an argument that every patient should receive the drugs regardless of contraindications. It suggests that relatively inexpensive, longstanding therapies can be underused even while the industry celebrates new classes of medicine.

The interviewer asked why effective medicines fail to reach patients soon enough. Palecek’s response focused on a health system organized by organ specialty even though patients experience cardiovascular, metabolic and renal illnesses together. He described integrated care as an attempt to close the handoffs between specialties and to monitor patients before kidney function deteriorates to the point of dialysis. This shifts the performance question from how many interventions a provider performs to whether the patient receives appropriate treatment at the right stage. It also identifies a concrete evaluation need: program outcomes should be compared with an appropriate baseline rather than equating outreach volume with improved health.

The GLP-1 outcome figures mentioned by Palecek were a 9% reduction in hospitalization during the first six months after dialysis initiation and a 17% improvement in mortality among treated kidney patients. Because the presentation was brief, it did not describe in detail the source population, comparator, study design or uncertainty around those figures. They are therefore useful as examples of what the executive regarded as promising, but not sufficient by themselves for making a clinical recommendation. Practical adoption would also require assessing who qualifies for therapy, potential contraindications, drug access and coordination with other treatments for advanced kidney disease.

5. Insights

Treatment Plus Delivery: Evaluating new medicines alongside care coordination and service design can improve their real-world impact.

Implications for South Korea: Korea could consider integrated chronic kidney disease management models that connect prescribing, multimorbidity care and longitudinal data.

System-Level Collaboration: Partnerships among providers, payers and technology developers could support earlier identification, adherence and outcomes-based care.

Report 21. The Drug is Only Half the Breakthrough_eng.pdf

Download PDF • 69KB